Morgan Stanley Reiterates Equal-Weight on Pacific Biosciences, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has reiterated an Equal-Weight rating on Pacific Biosciences (NASDAQ:PACB) and maintained a $13 price target.
August 04, 2023 | 6:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Pacific Biosciences and maintained a $13 price target.
The news is directly about Pacific Biosciences. Morgan Stanley's reiteration of an Equal-Weight rating and maintenance of a $13 price target indicates a neutral outlook for the stock in the short term. This could potentially impact investor sentiment and trading decisions.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100